HOPA 2024 Complete Bundle On Demand

UAN# 0465-0000-24-014-H99-P

Presenters:

• Lisa Janssen Carlson, PharmD, BCOP
• Elyse MacDonald, PharmD, MS, BCPS
• Jennifer Murphy, PharmD, BCOP

Learning Objectives:

1. Distinguish how historical occurrences have shaped the conduct of clinical trials in current day
2. Implement site-specific strategies, including trial design, for increased diversity, equity, and inclusion (DEI) in clinical trials
3. Design strategies to mitigate barriers for the implementation of DEI practices at the clinical trial site
4. Analyze the positive impacts of increased diversity in clinical trials
5. Create a plan for pharmacy to implement DEI strategies for patients participating in an oncology clinical trial

UAN# 0465-0000-24-016-H01-P

Presenter:

• Brian Primeaux, PharmD, BCOP

Learning Objectives:

1. Explain the structure and mechanism of action of chimeric antigen receptor (CAR) T-cell therapies
2. Interpret the primary literature on the use of CAR T-cell therapy for the treatment of non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM)
3. Discuss the role of CAR T-cell therapy in NHL and MM
4. Select the toxicity grade for a patient with cytokine release syndrome associated with CAR T-cell therapy
5. Create an appropriate management plan for a patient with toxicity associated with CAR T-cell therapy

UAN# 0465-0000-24-018-H04-P

Presenters:

• Chelsee Jensen, PharmD, BCOP
• Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA

Learning Objectives:

1. Describe the key steps in conducting a financial analysis for cancer drugs
2. Explain how cost should be calculated for use in a cancer drug financial analysis
3. Define key financial information needed when calculating margin, including revenue generated by the different types of reimbursement
4. Outline the steps needed to decide which product should be the “preferred” product based on a financial analysis
5. Summarize the reasons cost and margin should be considered when determining drug therapy

UAN# 0465-0000-24-021-H01-P

Presenter:

• Kelly Fritz, PharmD, BCOP

Learning Objectives:

1. Identify the main differences in adult glioma classifications based on World Health Organization (WHO) 2021 molecular characteristics
2. Explain the role of key molecular markers in glioma diagnosis, treatment, and overall prognosis
3. Apply the updated glioma classifications to historical treatment regimens in a patient case
4. Analyze recent clinical trial updates in the treatment of gliomas

UAN# 0465-0000-24-023-H01-P

Presenters:

• Justin Arnall, PharmD, BCOP
• Binni Kunvarjee, PharmD, BCOP

Learning Objectives:

1. Explain the role of the complement system and how therapeutic complement inhibition treats select complement-mediated hemolytic disorders
2. Examine the efficacy of complement inhibition as first-line therapy for atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH)
3. Identify considerations for initial complement inhibitor treatment selection and factors necessitating a change in therapeutic approach for aHUS and PNH
4. Analyze the efficacy of complement inhibition as adjunctive therapy for cold agglutinin disease
5. Outline the role of the pharmacist and drug-specific considerations in facilitating administration of complement inhibitor therapy in inpatient and outpatient settings

UAN# 0465-0000-24-025-H01-P

Presenter:

• Tara Higgins, PharmD, BCPPS, FPPA, FFSHP

Learning Objectives:

1. Summarize the current use of precision medicine in pediatric solid tumors
2. Explain the future use of targeted therapies in select pediatric solid tumors
3. Analyze advantages and disadvantages of utilizing commercially available targeted therapies within the pediatric solid tumor population
4. Apply precision medicine to patient cases

UAN# 0465-0000-24-027-H01-P

Presenter:

• Christine Barrett, PharmD, BCOP

Learning Objectives:

1. Review current guidelines for the treatment of recurrent and metastatic head and neck cancers
2. Interpret the latest data in recurrent and metastatic head and neck cancer
3. Recommend appropriate treatment for recurrent and metastatic head and neck cancer based on patient- and disease-specific factors
4. Discuss ongoing clinical trials for systemic therapy in head and neck cancer

UAN# 0465-0000-24-042-H01-P

Presenter:

• Dennis Marjoncu, PharmD, BCOP

Learning Objectives:

1. Review novel and expanded indication medications for myeloid conditions
2. Compare trial data for medications used in hematologic disorders
3. Differentiate novel adverse effects associated with new therapies
4. Discuss society guidelines for myeloid conditions and how novel data is incorporated into recommendations
5. Choose treatment plans for patient cases based on the data reviewed

UAN# 0465-0000-24-044-H01-P

Presenters:

• Amber Bradley Clemmons, PharmD, BCOP, FHOPA
• Emily Ketchum, PharmD, BCOP
• Mary Cash, PharmD, BCOP
• Erin Eberwein, PhamD, BCOP
• Eugene Przespolewski, PharmD, BCOP, DPLA
• Sandra Savignac, PharmD, M.Sc

Learning Objectives:

1. Describe data for the use of a continuous temperature monitoring device in adult patients at risk of febrile neutropenia
2. Describe the outcomes of this study evaluating the role of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate (MMF) among those undergoing allogeneic stem cell transplant with myeloablative conditioning
3. Upon completion, the participant will be able to explain the landscape of current resources provided to PGY-2 Oncology Residency Program Directors (ORPDs) and their level of professional fulfillment
4. Identify predictive factors of palbociclib dose reduction in patients with advanced or metastatic breast cancer

0465-0000-24-046-H01-P

Presenters:

• Tiba Al Sagheer, PharmD, BCOP, BCACP
• Matthew Chui, PharmD, BCOP

Learning Objectives:

1. Describe treatment updates to frontline Advanced Stage Hodgkin Lymphoma
2. Review treatment options for patients in the relapsed or refractory setting with a focus on incorporating novel agents
3. Apply treatment modalities for elderly patients with Hodgkin Lymphoma
4. Employ strategies for management of toxicities associated with checkpoint inhibitors and antibody-drug conjugates

UAN# 0465-0000-24-048-H03-P

Presenters:

• Michael Harrison
• Jeffrey Pilz, PharmD, MPA, MS, BCPS
• Peter Stuessy, PharmD, BCOP

Learning Objectives:

1. Discuss patient perspectives on impacts of anticancer drug shortages
2. Define the current anticancer drug shortage environment and its root causes
3. Demonstrate strategies that can be used to navigate anticancer drug shortages
4. Select ethical considerations to consider when allocating anticancer medications during shortages

UAN# 0465-0000-24-050-H01-P

Presenters:

• Raymond DeMatteo, PharmD, BCOP
• Adam Kahleifeh, PharmD, BCOP

Learning Objectives:

1. Describe the molecular diagnostic tests used in the evaluation of solid tumors
2. Outline the evidence for FDA approved precision medicine therapeutics based on molecular profiling
3. Recognize novel targets and their respective therapeutics that are used to treat specific solid tumors
4. Choose appropriate therapies based off genomic findings using patient cases
5. Discover developing therapeutics that are being explored for specific biomarkers in solid tumors

UAN# 0465-0000-24-029-H01-P

Presenters:

• Michael Buege, PhamD, BCOP
• Catherine Martin, PharmD, BCOP

Learning Objectives:

1. Recall key findings from recent trials of ibrutinib (front-line) and pirtobrutinib (R/R) in patients with MCL
2. Summarize current standard-of-care approaches for treatment of MCL in the front-line and R/R settings, including the role of autoHCT
3. Describe the epidemiology, pathophysiology, and characteristics of infant leukemia
4. Summarize literature guiding treatment of infant leukemia

0465-0000-24-031-H01-P

Presenters:

• Sarah Chehab, PharmD, BCOP
• Dazhi Liu, PharmD, BCOP

Learning Objectives:

1. Identify targeted therapies in various GI malignancies including gastric cancer and colorectal cancer
2. Evaluate clinical trials relating to targeted therapies in GI malignancies
3. Upon completion, participants will be able to describe the molecular landscape of HER2 alterations in patients with non-breast/non-gastric solid tumors
4. Upon completion, participants will be able to compare the clinical data of HER2 targeted therapies in a variety of non-breast and non-gastric cancers

UAN# 0465-0000-24-033-H01-P

Presenters:

• Nikki Ogle, PharmD, BCOP,
• Marie Parish, PharmD, BCOP, BCPS

Learning Objectives:

1. Identify challenges with payer mandates in the oncology landscape
2. Describe the process for biosimilar functionality implementation and maintenance, including identifying payer step edits, required institutional policies, and claim reimbursement analysis
3. Discuss the pharmacology of the endocannabinoid system​
4. Review the use of cannabinoids in select palliative care conditions

UAN# 0465-0000-24-052-H01-P

Presenter:

• Taylor Kujawa, PharmD
• Charlotte Wagner, PharmD, BCOP

Learning Objectives:

1. Review B-cell acute lymphoblastic leukemia (B-ALL) pathophysiology and general treatment principles
2. Describe the literature for blinatumomab in combination with a TKI upfront for Ph+ B-ALL
3. Construct an evidence-based treatment plan for a patient with B-ALL
4. Discuss logistical implications and the role of oncology stewardship with increased use of novel agents

UAN# 0465-0000-24-052-H01-P

Presenters:

• Emma Garrison, PharmD, BCOP
• Alison Gulbis, PharmD, BCOP
• Matthew Peery, PharmD
• Jordan Wallace, PharmD, BCOP

Learning Objectives:

1. Describe the role of career goals in selecting a career path
2. Explore various opportunities for professional development and career advancement
3. Discuss the transition from student/learner into a practitioner
4. Outline different ways to navigate new practitioner challenges

UAN# 0465-0000-24-056-H01-P

Presenter:

• Shannon Palmer, PharmD, BCOP

Learning Objectives:

1. Summarize the clinical features, pathophysiology, and grading for chronic graft versus host disease (cGVHD)
2. Describe front-line treatment for cGVHD and findings of the iNTEGRATE study
3. Review FDA approved agents for steroid refractory cGVHD - belumosudil(ROCKstar), ruxolitinib(REACH3), and ibrutinib
4. Discuss sequencing of agents, supportive care, and upcoming approvals for cGVHD agents

UAN# 0465-0000-24-058-H01-P

Presenters:

• Soniya Chandrasekhara, PharmD, BCOP
• Shahrier Hossain, PharmD, BCOP
• Melissa Royero, PharmD
• Kelsea Seago, PharmD, BCOP

Learning Objectives:

1. Identify the mechanism of action, history, and early uses of bispecific antibodies (BsAbs) in the setting of hematologic malignancies
2. Analyze the available literature supporting the use of BsAbs in the management of relapsed/refractory multiple myeloma
3. Interpret the available literature supporting the use of BsAbs in the treatment of relapsed/refractory follicular lymphoma and relapsed/refractory diffuse large b-cell lymphoma
4. Describe the role of the pharmacist to ensure safe and effective use of BsAbs in the setting of hematologic malignancies by applying strategies to mitigate and manage toxicities
5. Apply strategies to overcome operational challenges associated with the use of BsAbs to improve the quality of care for patients including site of care, REMS, and cost-related considerations

UAN# 0465-0000-24-035-H01-P

Presenters:

• Karen Fancher, PharmD, BCOP
• Abby Kim, PharmD, BCOP

Learning Objectives:

1. Upon completion, participants will be able to describe the challenges of navigating ethical conflicts in oncology pharmacy practice
2. Upon completion, participants will be able to identify solutions to an example ethical conflict in oncology pharmacy practice
3. Outline basics of gene therapy and describe current hematology landscape and pipeline
4. Identify barriers to care and uptake of available gene therapies based on the value proposition

UAN# 0465-0000-24-037-H01-P

Presenters:

• Aseala Abousaud, PharmD, BCOP
• Brooke Adams, PharmD, BCOP

Learning Objectives:

1. Describe the literature and adverse effect profile of mosunetuzumab, epcoritamab and glofitamab in relapsed/refractory lymphoma
2. Analyze real world implications of mosunetuzumab, epcoritamab and glofitamab in relapsed/refractory lymphoma
3. Describe the roles and side effect profiles of the three-novel BsABs approved for the treatment of RRMM
4. Discuss the sequencing of these agents in the treatment of RRMM

UAN# 0465-0000-24-039-H01-P

Presenters:

• Emily Graham, PharmD, BCOP, MS
• Danielle Roman, PharmD, BCOP

Learning Objectives:

1. Summarize recent publications on the use of chemoimmunotherapy in endometrial cancer and their impact on clinical practice
2. Discuss the role and application of molecular testing in endometrial cancer
3. Summarize the evidence supporting the use of CDK4/6 inhibitors for the treatment of early-stage breast cancer
4. Formulate treatment plans incorporating CDK4/6 inhibitors for appropriate patients with early-stage breast cancer

UAN# 0465-0000-24-060-H01-P

Presenters:

• Kelly Brunk, PharmD, BCOP

Learning Objectives:

1. Define criteria for determining patient eligibility for cisplatin-based therapy in the management of locally advanced or metastatic urothelial cancer (la/mUC)
2. Review therapies used for patients with la/mUc
3. Explain the role of enfortumab vedotin-ejfv plus pembrolizumab as a first-line treatment for la/mUC
4. Select appropriate prevention and monitoring strategies to address complications and toxicities and optimize outcomes associated with the treatment of la/mUC

UAN# 0465-0000-24-062-H01-P

Presenters:

• Megan May, PharmD, BCOP, FHOPA, FAPO
• Marie Sirek, PharmD, BCACP, CPP
• Mary Walter, PharmD, BCOP

Learning Objectives:

1. Explore the utility of current biomarker testing to guide treatment for patients with human epidermal growth factor receptor 2 (HER2)-low breast cancer
2. Upon completion, participant will be able to describe alpelisib induced hyperglycemia and understand optimal pharmacologic management.
3. Select an appropriate treatment option for a patient with metastatic castrate-resistant prostate cancer and a pathogenic mutation in a homologous recombination repair gene

UAN# 0465-0000-24-064-H01-P

Presenters:

• Leila Rostamnjad, PharmD, BCOP
• Mya Tran, PharmD, BCOP

Learning Objectives:

1. Outline the treatment overview of NSCLC with driver alterations
2. Describe clinical dilemma in clinical settings related to the use of immunotherapy in oncogene-addicted NSCLC
3. Review data evaluating the current treatment landscape utilizing immunotherapy in NSCLC with oncogenic drivers
4. Apply therapeutic strategies for the treatment of NSCLC with oncogenic drivers

UAN# 0465-0000-24-066-H01-P

Presenters:

• Alexandre Chan, PharmD, MPH, FCCP, FISOPP, BCPS, BCOP, Aph,
• Debbie Liang, PharmD, BCCCP
• Angela Stover, PhD

Learning Objectives:

1. Describe the challenges faced by racial/ethnic minorities with regards to symptom management
2. Discuss the benefits of an electronic patient reported outcome (ePRO) system for symptom management
3. Describe the important role that patient-reported outcome measures (PROMs) can play in monitoring side effects
4. Apply a real-world example of pharmacists using a verbal PROM integrated in the electronic health record to monitor side effects during oral oncolytic treatment

UAN# 0465-0000-24-068-H01-P

Presenter:

• Clement Chung, PharmD, BCOP, MS, BCPS

Learning Objectives:

1. Describe the general pathophysiology and treatment initiation parameters for CLL
2. Differentiate the sequencing of single agents vs. combination therapies in newly diagnosed, and relapsed or refractory CLL
3. Illustrate specific treatment plans based on efficacy, toxicity, biomarkers, and other pertinent considerations
4. Evaluate the use of biomarkers to prognosticate disease outcomes or predict response to small molecule inhibitors

UAN# 0465-0000-24-070-H99-P

Presenter:

• Porscha, PharmD, CPGx

Learning Objectives:

1. Recognize the significance of pharmacogenetics and genomics in precision oncology
2. Highlight the role of variants of unknown/uncertain significance (VUS) in understanding genetic mutations
3. Showcase the importance of implementing Diversity, Equity, and Inclusion (DEI) measures in genetic research
4. Inspire pharmacist collaboration with future directions and research in pharmacogenetics and genomics

UAN# 0465-0000-24-072-H99-P

Presenter:

• Jennifer Espiritu, PharmD, BCOP, CCRP

Learning Objectives:

1. Identify factors contributing to the current crisis in clinical research
2. Recognize areas where pharmacists can impact clinical trial conduct
3. Describe the requirements needed for pharmacists to prescribe investigational agents
4. Discuss collaborative practice integration at a large academic medical center